Aethlon Medical Q1 operating expenses fall on lower professional fees
AEMD•Clinical program progress
Aethlon said it dosed the first participant in the final cohort of its Phase 1 oncology study for Hemopurifier.
The company also reported preliminary biomarker signals supporting continued evaluation of Hemopurifier.
Cash position and financing
Aethlon Medical ended the quarter with $4.9 million in cash and said it raised $4.0 million after the quarter through a stock offering.
The company expects its cash resources to fund operations for at least the next 12 months.
Operating expenses and loss
US clinical-stage therapeutic firm Aethlon Medical said fiscal first-quarter operating expenses fell 12% year over year, reducing operating loss.
The company said lower professional fees and reduced general and administrative and preclinical research costs drove the decline in operating expenses.
Analyst coverage and valuation
The current average analyst rating on the shares is hold, with no strong buy or buy recommendations, two hold ratings and no sell or ratings.
